At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 214 enrolled
Drug / intervention
Basmisanil +1 moredrug
Likely dose
Basmisanil 80 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics
In Brief
A Phase 2 clinical trial evaluating Basmisanil and Placebo for Schizophrenia. Completed, enrolled 214 participants across 37 sites.
Detailed Summary
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 3, 2016
Enrollment StartNov 30, 2016
Primary CompletionDec 12, 2019
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.7 years ago
Interventions
Basmisanildrug
Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
Placebodrug
Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.